Associated Genetic Biomarkers
NCI Definition: A malignant neoplasm of the pleura or peritoneum, arising from mesothelial cells. It is associated with exposure to asbestos. 
Malignant mesotheliomas most frequently harbor alterations in BAP1, CDKN2A, NF2, CDKN2B, and TP53 .
BAP1 Mutation, CDKN2A Loss, CDKN2B Loss, NF2 Mutation, and SETD2 Mutation are the most common alterations in malignant mesothelioma .
There are 6 clinical trials for malignant mesothelioma, of which 5 are open and 1 is completed or closed. Of the trials that contain malignant mesothelioma as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (4 open).
BAP1 and NF2 are the most frequent gene inclusion criteria for malignant mesothelioma clinical trials .
Abemaciclib, atezolizumab, and bemcentinib are the most common interventions in malignant mesothelioma clinical trials.
Significant Genes in Malignant Mesothelioma
BAP1 is altered in 34.94% of malignant mesothelioma patients .
BAP1 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains BAP1 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (0 open) .
NF2 is altered in 18.62% of malignant mesothelioma patients .
NF2 is an inclusion eligibility criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and malignant mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.